The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement. Thus, an appropriate diagnostic algorithm cannot exclude biological and functional assessment of the peripheral airways. Similarly, achievement of optimal control of the disease and appropriate management of specific phenotypes of asthma should be based on drugs (and delivery options) able to distribute uniformly along the bronchial tree and to reach the most peripheral airways. Products developed with the Modulite((R)) technology platform have been demonstrated to meet these aims. Recent real-life studies have shown clearly that extra-fine fixed-combination inhaled therapy provides better asthma control than non-extra-fine formulations, thus translating the activity of the drugs into greater effectiveness in clinical practice. We suggest that in patients with incomplete asthma control despite good lung function, involvement of the peripheral airways should always be suspected. When this is the case, treatments targeting both the large and small airways should be used to improve asthma control. Above all, it is emphasized that patient adherence with prescribed medications can contribute to clinical success, and clinicians should always be aware of the role played by patients themselves in determining the success or failure of treatment.

Scichilone, N., Spatafora, M., Battaglia, S., Arrigo, R., Benfante, A., Bellia, V. (2013). Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations. JOURNAL OF ASTHMA AND ALLERGY, 6, 11-21 [10.2147/JAA.S14743].

Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations

SCICHILONE, Nicola Alessandro;SPATAFORA, Mario;BATTAGLIA, Salvatore;ARRIGO, Rita;BENFANTE, Alida;BELLIA, Vincenzo
2013-01-01

Abstract

The mainstay of management in asthma is inhalation therapy at the target site, with direct delivery of the aerosolized drug into the airways to treat inflammation and relieve obstruction. Abundant evidence is available to support the concept that inflammatory and functional changes at the level of the most peripheral airways strongly contribute to the complexity and heterogeneous manifestations of asthma. It is now largely accepted that there is a wide range of clinical phenotypes of the disease, characterized primarily by small airways involvement. Thus, an appropriate diagnostic algorithm cannot exclude biological and functional assessment of the peripheral airways. Similarly, achievement of optimal control of the disease and appropriate management of specific phenotypes of asthma should be based on drugs (and delivery options) able to distribute uniformly along the bronchial tree and to reach the most peripheral airways. Products developed with the Modulite((R)) technology platform have been demonstrated to meet these aims. Recent real-life studies have shown clearly that extra-fine fixed-combination inhaled therapy provides better asthma control than non-extra-fine formulations, thus translating the activity of the drugs into greater effectiveness in clinical practice. We suggest that in patients with incomplete asthma control despite good lung function, involvement of the peripheral airways should always be suspected. When this is the case, treatments targeting both the large and small airways should be used to improve asthma control. Above all, it is emphasized that patient adherence with prescribed medications can contribute to clinical success, and clinicians should always be aware of the role played by patients themselves in determining the success or failure of treatment.
2013
Scichilone, N., Spatafora, M., Battaglia, S., Arrigo, R., Benfante, A., Bellia, V. (2013). Lung penetration and patient adherence considerations in the management of asthma: Role of extra-fine formulations. JOURNAL OF ASTHMA AND ALLERGY, 6, 11-21 [10.2147/JAA.S14743].
File in questo prodotto:
File Dimensione Formato  
Scichilone - J Asthma Allergy 2013.pdf

Solo gestori archvio

Descrizione: Articolo principale
Dimensione 625.09 kB
Formato Adobe PDF
625.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/70907
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 33
social impact